MALARIA ERADICATION
THROUGH VACCINATION
Sanaria's vaccines are intended to be used to prevent malaria in individuals and, in combination with other malaria control measures, to halt transmission of and eliminate malaria from communities.
Employees of the Month: Mei-Chun Chen and Ramon Dizon Jr.
The Sanaria employees of the month for October 2023 are Mei-Chun Chen and Ramon Dizon Jr.. Mei is a member of the clinical team at Sanaria and was nominated for employee of the month for her immeasurable contributions to the success of Sanaria. Ramon is a member of the Materials Management team and was nominated for employee of the month for performing his duties competently, expeditiously and with a smile, always pleasant, always willing to help and always joy to work with.
Sanaria and Seattle Children’s Research Institute host the first live i-PfSPZ-C meeting since 2019 in Seattle, WA, USA
From November 3rd-4th, 2022, Sanaria and Seattle Children's Research Institute hosted 289 researchers from 86 institutions from 28 countries in person and virtually at the International (i) - Plasmodium falciparum (PfSPZ) - Consortium (C) meeting to further a collaborative approach for presentation of data and setting research and clinical development strategies for PfSPZ based vaccines and products.
Sanaria collaborators at Seattle Children’s Research Institute report on safety and efficacy of early arresting, non-replicating, genetically attenuated malaria sporozoite vaccine.
In a publication in Science Translational Medicine, Sean Murphy, Stefan Kappe and colleagues at Seattle Children’s Research Institute (SCRI) report the safety and efficacy against controlled human malaria infection of the administration by mosquito bite of Plasmodium falciparum (Pf) parasites attenuated by deletion of three genes.
United to Beat Malaria and Shot@Life Delegation Visit Sanaria
On Thursday 28 July 2022, a team from the United Nations Foundation, including United to Beat Malaria and Shot@Life visited Sanaria Inc.
COLLABORATORS PUBLISH ARTICLE IN NATURE COMMUNICATIONS: PLASMODIUM FALCIPARUM 7G8 CHALLENGE PROVIDES CONSERVATIVE PREDICTION OF EFFICACY OF PFNF54-BASED PFSPZ VACCINE IN AFRICA
ROCKVILLE, MD, USA – July 12, 2022 – Sanaria Inc., University of Maryland School of Medicine, Naval Medical Research Center, National Institutes of Health (USA), University of Bamako Malaria Research and Training Center (Mali), and University of Tübingen (Germany) published results in Nature Communications showing Plasmodium falciparum 7G8 human challenge trials provide a conservative prediction of efficacy of PfNF54-based PfSPZ Vaccine in Africa.
Prince Ned Nwoko Foundation Visits Sanaria
On Tuesday, June 21st 2022, Sanaria was pleased to welcome Prince Ned Nwoko (virtually) and Mr. Chuks Anyaduba to Sanaria to discuss future interactions. Sanaria looks forward to a long a fruitful partnership as we push together towards our shared goal of a PfSPZ vaccine that will help to eliminate malaria. Please see link for Prince Ned Nwoko Foundation’s press release on this visit.
An Urgent Need for Malaria Vaccines
Sanaria has an innovative approach to malaria vaccines using Plasmodium falciparum (Pf) sporozoites (SPZ) as the platform technology for immunizing people against malaria infection. The proven effective results of this approach are documented in Sanaria’s publications.
Global Collaboration: The I-PfSPZ Consortium
Semi-annually, Sanaria organizes the international PfSPZ Consortium (i-PfSPZ-C) meeting for our partners, collaborators and funders where we analyze, present and discuss our findings prior to publication. The i-PfSPZ-C allows our collaborators and partners to share their work, modify research and clinical plans based on the consortium efforts and map out future funding needs.
Subscribe
Our Malaria Vaccine Pipeline
Innovative routes to success. A major impact in global health.